BiondVax appoints Dobbelstein to Scientific Advisory Board

BiondVax Pharmaceuticals announced that Professor Dr. med. Matthias Dobbelstein has been appointed a member of the company’s Scientific Advisory Board, SAB. Professor Dobbelstein has served as Director of the Institute of Molecular Oncology at the University Medical Center Gottingen, Germany since 2005 and is also an Associate Member of the Max Planck Institute for Multidisciplinary Sciences. In addition, Professor Dobbelstein, together with Professor Gorlich, is collaborating with BiondVax under a five-year strategic research agreement for the discovery, characterization and cloning of additional NanoAbs for the treatment of autoimmune diseases